Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy

BACKGROUND: In cancer therapy, higher-resolution tumor-agnostic biomarkers that predict response to immune checkpoint inhibitor (ICI) therapy are needed. Mutation signatures reflect underlying oncogenic processes that can affect tumor immunogenicity, and thus potentially delineate ICI treatment resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamatsu, Shiro, Hamanishi, Junzo, Brown, J B, Yamaguchi, Ken, Yamanoi, Koji, Murakami, Kosuke, Gotoh, Osamu, Mori, Seiichi, Mandai, Masaki, Matsumura, Noriomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289027/
https://www.ncbi.nlm.nih.gov/pubmed/35868660
http://dx.doi.org/10.1136/jitc-2022-004831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289027/
https://www.ncbi.nlm.nih.gov/pubmed/35868660
http://dx.doi.org/10.1136/jitc-2022-004831

Ejemplares similares